Anatomical main group
A – ALIMENTÄRES SYSTEM UND STOFFWECHSEL
87Decisions
184Patient groups
Added benefit by patient group
- Major2
- Considerable9
- Minor24
- Non-quantifiable29
- Not proven120
Subgroups
- A03 MITTEL BEI FUNKTIONELLEN GASTROINTESTINALEN STÖRUNGEN 1 decision
- A04 ANTIEMETIKA UND MITTEL GEGEN ÜBELKEIT 1 decision
- A05 GALLEN- UND LEBERTHERAPIE 7 decisions
- A06 MITTEL GEGEN OBSTIPATION 2 decisions
- A07 ANTIDIARRHOIKA UND INTESTINALE ANTIPHLOGISTIKA/ANTIINFEKTIVA 2 decisions
- A08 ANTIADIPOSITA, EXKL. DIÄTETIKA 3 decisions
- A10 ANTIDIABETIKA 45 decisions
- A16 ANDERE MITTEL FÜR DAS ALIMENTÄRE SYSTEM UND DEN STOFFWECHSEL 26 decisions
Decisions, newest first
- 2026-08-20MounjaroTirzepatidNot proven
- 2026-08-06TeizeildTeplizumabNon-quantifiable
- 2026-03-05RezdiffraResmetiromNot proven
- 2026-01-22SephienceSepiapterinNon-quantifiable
- 2025-09-04Lyvdelzi (previously Seladelpar Gilead)SeladelparMinor
- 2025-09-04NulibryFosdenopterinNon-quantifiable
- 2025-08-21ImcivreeSetmelanotidNon-quantifiable
- 2025-06-18CerdelgaEliglustatNon-quantifiable
- 2025-04-03IqirvoElafibranorMinor
- 2025-02-20AwiqliInsulin icodecNot proven
- 2025-02-20AwiqliInsulin icodecNot proven: 4 of 4 patient groups
- 2025-02-06LivmarliMaralixibatNon-quantifiable
- 2024-07-04LoargysPegzilarginaseNon-quantifiable
- 2024-06-20JardianceEmpagliflozinNot proven
- 2024-05-02MounjaroTirzepatidMinor: 1 of 8 patient groupsNot proven: 7 of 8 patient groups
- 2024-03-21ElfabrioPegunigalsidase alfaNot proven
- 2024-02-15GalafoldMigalastatNot proven
- 2024-02-01PombilitiCipaglucosidase alfaMinor
- 2024-02-01JardianceEmpagliflozinNot proven
- 2023-11-02ImcivreeSetmelanotidNon-quantifiable
- 2023-09-21TrulicityDulaglutidNot proven
- 2023-08-17ForxigaDapagliflozinMinor
- 2023-07-06LivmarliMaralixibatNon-quantifiable
- 2023-04-06ZokinvyLonafarnibNon-quantifiable
- 2023-02-02UpstazaEladocagen exuparvovecNon-quantifiable
- 2022-12-15BrineuraCerliponase alfaMajor
- 2022-12-01ImcivreeSetmelanotidNon-quantifiable
- 2022-09-15JardianceEmpagliflozinMinor
- 2022-06-16ForxigaDapagliflozinNot proven: 2 of 2 patient groups
- 2022-05-19SteglatroErtugliflozinNot proven: 8 of 8 patient groups
- 2022-03-03BylvayOdevixibatMinor
- 2022-02-17ForxigaDapagliflozinConsiderable: 1 of 2 patient groupsMinor: 1 of 2 patient groups
- 2022-01-06JardianceEmpagliflozinMinor
- 2021-11-04LibmeldyAtidarsagen autotemcelMajor: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2021-07-01OxlumoLumasiranNon-quantifiable
- 2021-06-03KanumaSebelipase alfaNon-quantifiable: 2 of 2 patient groups
- 2021-05-20ForxigaDapagliflozinConsiderable
- 2020-11-05RizmoicNaldemedinNot proven: 2 of 2 patient groups
- 2020-10-15SuliquaInsulin glargin/LixisenatidNot proven: 2 of 2 patient groups
- 2020-10-15Givlaari GivosiranConsiderable
- 2020-09-03DificlirFidaxomicinConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2020-07-16TrulicityDulaglutidMinor: 2 of 5 patient groupsNot proven: 3 of 5 patient groups
- 2020-04-02StrensiqAsfotase alfaNon-quantifiable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-12-19PalynziqPegvaliaseNon-quantifiable
- 2019-12-19ForxigaDapagliflozinMinor: 3 of 8 patient groupsNot proven: 5 of 8 patient groups
- 2019-12-19XigduoDapagliflozin/MetforminMinor: 3 of 6 patient groupsNot proven: 3 of 6 patient groups
- 2019-11-22GlyxambiEmpagliflozin/LinagliptinNot proven
- 2019-07-04RavictiGlycerolphenylbutyratNon-quantifiable
- 2019-05-16TresibaInsulin degludecNot proven: 2 of 2 patient groups
- 2019-05-02OzempicSemaglutidMinor: 3 of 8 patient groupsNot proven: 5 of 8 patient groups
- 2019-03-22JanuviaSitagliptinMinor
- 2019-03-22MepseviiVestronidase alfaNon-quantifiable
- 2019-03-22MyaleptaMetreleptinNon-quantifiable: 2 of 2 patient groups
- 2018-12-20LamzedeVelmanase alfaNon-quantifiable
- 2018-11-01SteglujanErtugliflozin/SitagliptinNot proven
- 2018-09-20SialanarGlycopyrroniumNon-quantifiable
- 2018-08-16SuliquaInsulin glargin/LixisenatidNot proven: 2 of 2 patient groups
- 2018-08-16RavictiGlycerolphenylbutyratNon-quantifiable
- 2018-04-05XermeloTelotristatethylNon-quantifiable
- 2018-03-16VimizimElosulfase alfaMinor
- 2018-02-01KomboglyzeSaxagliptin/MetforminNot proven
- 2017-01-19RevestiveTeduglutidNon-quantifiable
- 2016-12-15JanumetSitagliptin/MetforminNot proven: 3 of 3 patient groups
- 2016-12-15JanuviaSitagliptinNot proven: 4 of 4 patient groups
- 2016-12-15KomboglyzeSaxagliptin/MetforminNot proven: 2 of 2 patient groups
- 2016-12-15OnglyzaSaxagliptinNot proven: 4 of 4 patient groups
- 2016-09-01SynjardyEmpagliflozin/MetforminNot proven: 6 of 6 patient groups
- 2016-09-01JardianceEmpagliflozinConsiderable: 4 of 10 patient groupsMinor: 1 of 10 patient groupsNot proven: 5 of 10 patient groups
- 2016-02-04XultophyInsulin degludec/LiraglutidNot proven
- 2016-02-04AkynzeoNetupitant/PalonosetronNot proven: 2 of 2 patient groups
- 2015-10-15XultophyInsulin degludec/LiraglutidNot proven: 3 of 3 patient groups
- 2015-10-01CerdelgaEliglustatNon-quantifiable
- 2015-08-20TresibaInsulin degludecNot proven: 3 of 3 patient groups
- 2015-05-21GalvusVildagliptinNot proven
- 2015-02-19RevestiveTeduglutidMinor
- 2015-02-05VokanametCanagliflozin/MetforminNot proven: 3 of 3 patient groups
- 2014-11-06OrphacolCholsäureNon-quantifiable
- 2014-10-16TresibaInsulin degludecNot proven
- 2014-09-04InvokanaCanagliflozinNot proven: 5 of 5 patient groups
- 2013-10-17ConstellaLinaclotidNot proven
- 2013-10-01KomboglyzeSaxagliptin/MetforminNot proven
- 2013-10-01GalvusVildagliptinNot proven: 4 of 4 patient groups
- 2013-10-01EucreasVildagliptin/MetforminNot proven: 3 of 3 patient groups
- 2013-09-05Lyxumia LixisenatidNot proven: 4 of 4 patient groups
- 2013-07-04DificlirFidaxomicinConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2013-05-16TrajentaLinagliptinNot proven
- 2013-02-21TrajentaLinagliptinNot proven: 3 of 3 patient groups
Data status: 2026-10-29